Setback for Incivek | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Hepatitis C Management: A Flu-Fighting Berry

Back to News Homepage
Next

Interferon-Free Hep C Combos to Watch for in 2013

Setback for Incivek

The Editors at Hepatitis Central
December 21, 2012

Print this page

Now burdened with a mandatory black box warning, the Hepatitis C drug Incivek could lead to a potentially fatal skin rash.

Vertex’s Hepatitis C Drug Receives Another Blow With FDA Warning

Published December 19, 2012

Dow Jones Newswires

The Food and Drug Administration on Wednesday placed a new label on Vertex Pharmaceuticals Inc.’s (VRTX) hepatitis C drug Incivek, warning patients that the drug has caused fatal skin rashes in some patients.

Two patients died after developing severe skin rashes while taking Incivek, used to treat the viral liver disease, the FDA said. The warning label, known as a “black box warning” for its prominent placement and black border, is the most serious warning issued by the regulator, and is a further blow to Vertex’s hepatitis C program.

Continue reading this entire article:http://www.foxbusiness.com/news/2012/12/19/vertex-hepatitis-c-drug-receives-another-blow-with-fda-warning/

 

18 Comments
Share
Share
Previous

Hepatitis C Management: A Flu-Fighting Berry

Back to News Homepage
Next

Interferon-Free Hep C Combos to Watch for in 2013

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.